INTRODUCTION
Glucuronidation is a major form of phase II xenobiotic metabolism, which is catalyzed by isoforms of the UDP-glucuronosyltransferase (UGT) family. UGTs are promiscuous enzymes capable of conjugating structurally diverse substrates. UGTs are constitutively expressed in a tissue-specific manner, with their expression and activity altered by genetic and environmental factors (Tukey and Strassburg, 2000) . While some UGTs exist only in extra-hepatic tissues, most UGTs are expressed abundantly in the liver (Tukey and Strassburg, 2000; Miners et al., 2006) . Although UGT isoforms vary between species, several inter-species homologues have been identified. Humans and rats have several orthologous UGTs, including 1A1, 1A3, 1A6, and 1A10. In general, rats have an overall greater capacity for glucuronidation than humans (Elsby et al., 2001; Völkel et al., 2002) . Along with the required cofactor uridine 5'diphosphoglucuronic acid (UDPGA), UGTs catalyze the synthesis of a β -D-glucuronide conjugate. Glucuronide conjugates are generally less biologically active and are more readily excreted than their parent substrates, making UGTs key players in the regulation of xenobiotic metabolism and toxicity.
Genistein [4',5,7-trihydroxyisoflavone] is a natural phytoestrogen abundantly present in soybeans. Since nearly sixty percent of processed foods contain soy, humans consume a nearly continuous supply of genistein in their everyday diet (Patisaul and Jefferson, 2010) . The pleiotropic effects of genistein remain controversial. While some laboratories report therapeutic effects of genistein such as chemoprevention, improved bone health, and amelioration of menopausal symptoms (Goldwyn et al., 2000; Evans et al., 2010) , other groups emphasize the phytoestrogen's adverse health effects, namely endocrine disruption (Jefferson et al., 2005; Casanova et al., 1999) . In both humans and rats, genistein causes precocious puberty and altered 5 DMD #42366 menstrual cycles (Strom et al., 2001; Casanova et al., 1999) . Additional adverse effects of genistein in rats include inhibited embryonic development and impaired spatial learning (Xing et al., 2010; Ball et al., 2010) .
Bisphenol A [(BPA) 4,4'-isopropylidenediphenol] is a synthetic monomer used in the synthesis of polycarbonate plastics and epoxy resins. BPA is a fairly ubiquitous compound, found as a common component in plastic baby bottles, as well as food and beverage containers.
BPA can leach from plastic containers into contents, especially when containers are exposed to heat and/or excessive wear, placing humans at a direct risk of exposure (Brede et al., 2003) .
BPA has estrogenic activity both in vitro and in vivo across numerous species (Kuiper et al., 1998; Perez et al., 1998; vom Saal et al., 1998) . Endocrine disrupting properties of BPA are routinely reported, and include inhibited embryonic development, altered postnatal growth rate, and induction of precocious puberty (Xing et al., 2010; Howdeshell et al., 1999) .
The UGT isoforms that are primarily responsible for the glucuronidation of genistein and BPA have been identified. The primary human UGTs implicated in the glucuronidation of genistein are hepatic UGTs 1A1, 1A6, and 1A9, as well as extra-hepatic UGTs 1A10 and 2B17 (Doerge et al., 1999; Pritchett et al., 1998; Tang et al., 2009; Liu et al., 2007) . Although the predominant UGTs responsible for the glucuronidation of genistein in rats have not been definitively identified, they are suspected to be UGTs 1A1, 1A6, and/or 1A10, since these isoforms are orthologous to the human UGTs (Tukey and Strassburg, 2000) . The predominant UGT responsible for the glucuronidation of bisphenol A in rats is UGT2B1, which is homologous to human UGTs 2B7 and 2B17, neither of which is the primary UGT involved in human BPA glucuronidation (Elsby et al., 2001) . Instead, human UGT2B15 is the primary UGT responsible for BPA's glucuronidation in humans (Hanioka et al., 2008a) 6 DMD #42366 Genistein and BPA share common metabolic pathways, with glucuronides being the predominant conjugate of each substrate formed in both human and rat liver microsomes. In addition to similar metabolism, genistein and BPA also exhibit comparable adverse effects of endocrine disruption when individuals are exposed during gestation and/or neonatal development. Humans and rats are routinely exposed to both endocrine disrupting compounds simultaneously in their everyday lives, and interactions between bisphenol A and genistein have been observed both in vitro and in vivo, warranting the analysis of genistein and BPA in a coexposure scenario (Xing et al., 2010; Dolinoy et al., 2007) . The goal of the present study was to investigate the inhibitory effect of BPA on the glucuronidation of genistein in vitro during simultaneous exposure to both endocrine disrupting compounds. Hepatic UGT inhibition was investigated in HLMs and RLMs using binary incubations of BPA and genistein. Sample Preparation: Analytes were isolated from their matrix using SPE with Bond
Elut Plexa cartridges and sequential additions of elution solvents ethyl acetate, methanol, and acetonitrile, as previously described by Coughlin et al., 2011 . SPE extracts were evaporated to dryness under vacuum and a stream of nitrogen before being reconstituted in 100 μ L of 50% acetonitrile in water.
Standard Solutions: Initial genistein stock solutions were prepared by dissolving genistein in methanol; BPA, BPA gluc, and genistein gluc were initially dissolved in acetonitrile.
All subsequent standards, ranging from 1 µg/mL to 1000 µg/mL, were prepared via serial dilution in acetonitrile and were stored at -20ºC.
Blank Controls: Two sets of blank controls were used: incubation blanks and SPE blanks. Incubation blank controls contained all of the same reagents and substrates as the samples, however, the blanks were terminated via addition of ice-cold acetonitrile prior to 9 DMD #42366 initiation of the reaction with UDPGA. SPE blank controls contained high purity water in place of standard solutions, and were processed alongside samples during SPE using all of the same supplies and reagents. The use of blank controls is especially important when analyzing ubiquitous compounds such as BPA, which is known to be prevalent in numerous laboratory supplies due to its use as a plasticizer (Stiles et al., 2007) . The use of plastics was minimized wherever possible, such as using glass incubation vials instead of plastic, in an effort to reduce contamination with BPA.
Analytical Conditions: Analytical conditions were similar to those optimized by Coughlin et al., 2011, with 
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The effects of varying concentrations of BPA on glucuronidation activity in HLMs are shown in Figure 4 . The IC 50 value of BPA for genistein glucuronidation in HLMs was 37.0 μ M.

DISCUSSION
The work presented here shows that BPA inhibits the glucuronidation activity of genistein in both human and rat liver microsomes. The glucuronide is the predominant metabolite of genistein formed in both humans and rats. Inhibition of genistein's glucuronidation therefore increases the bioavailability of genistein in the presence of BPA, thus allowing genistein to have a prolonged pharmacological effect. Extended biological action of genistein could exacerbate the compound's adverse effects, especially among populations that are particularly vulnerable to the endocrine disrupting effects of the natural phytoestrogen, such as neonates. Alternatively, metabolism of genistein and BPA could be transferred to susceptible extra-hepatic organs, further contributing to endocrine disruption. Such an alteration in metabolic capacity is noteworthy, considering that both humans and laboratory rodents are glucuronidation observed between human and rat liver microsomes is that different UGT isoforms may be responsible for genistein's metabolism in the different species. It is reasonable to consider that UGT isoforms are present at different levels in HLMs as they are in RLMs, thus contributing to different glucuronidation capacities between the two species. Additionally, it has been previously reported that BPA may inhibit the activity of human UGT 1A6, which is one of the key isoforms responsible for the metabolism of genistein (Hanioka et al., 2008b) . This interaction could be implicated in the altered metabolism of genistein observed during binary exposures in HLMs, and may help to explain why the glucuronidation rate of BPA appears to be independent of the presence of genistein (previous experiments, data not shown).
Interactions between BPA and genistein and their subsequent biological effects have been genistein and BPA; that may be synergistic or antagonistic depending upon the level and species selection. The study described in this paper contributes to this growing body of research, and highlights the complexity of outcomes that occur with co-exposures of these endocrine disrupting compounds.
In vitro analyses offer distinct advantages, but they are also limited in their utility.
Xenobiotic incubations with liver microsomes provide a great model for quick screenings of drug-to-drug interactions. Since the majority of predominant UGTs involved in the metabolism of BPA (rat UGT 2B1, human UGT 2B15) and genistein (UGTs 1A1, 1A6, and 1A9) are hepatically expressed, the glucuronidation of genistein in the absence and presence of BPA can be easily assessed using liver microsomes. Overall conjugation pathways, however, cannot be investigated using liver microsomes, due to their inherent limited capacity for sulfation. Finally, studies using liver microsomes exclude the analysis of enzymes that are expressed extrahepatically, whereas in vivo studies allow for the analysis of the contribution of extra-hepatic as well as hepatic enzymes in the metabolism of xenobiotics.
Potential human risk from exposures to xenobiotics is often assessed by data generated from animal models. Such a method is often sufficient, since the animal data frequently mirrors human data. In some circumstances, however, data generated from laboratory animals does not directly parallel the effects observed in humans, and alternate models are then required to predict risk to human health. The data presented here offer such an example of an incidence where animal data and human data do not match at the levels of genistein and BPA tested, and therefore human risk assessment for co-exposures to genistein and BPA should not necessarily be based solely upon data generated from rat models.
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Countless xenobiotics share the metabolic pathway of glucuronidation, however not all xenobiotics exhibit similar biological endpoints and increased susceptibility to adverse effects when exposed during particular windows of exposure. Additionally, practical binary exposure scenarios do not abound for all compounds. Genistein and BPA make for a unique mixture of xenobiotics to be investigated simultaneously due to their common metabolic pathways, similar biological effects, and prevalent everyday co-exposures.
In conclusion, BPA induced non-competitive inhibition for genistein glucuronidation in In absence of BPA, V max = 3.14 ± 0.26 nmoles/min/mg and K m = 58.3 ± 14 μM. In presence of BPA, V max = 3.57 ± 0.34 nmoles/min/mg and K m = 96.5 ± 22 μM.
